6th November 2020
4th November 2020
18th October 2018
Medicine Compliance Aid Stability
Vancocin · Flynn Pharma Ltd
Flynn Pharma Ltd
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Powder is hygroscopic. Protect from light and store in airtight container. Maximum 7 days in MCA.
1st April 2015
Lactation Safety Information
Not absorbed from the infant's GI tract
Small amounts in breast milk
24th September 2020
AeroVanc · Cystic fibrosis-associated MSRA lung infections - dry powder form in a capsule-based device
Development and Regulatory status
Phase III Clinical Trials
Dry powder inhalation formulation of vancomycin, a glycopeptide antibiotic.
Prevalence is 1 in 2,500 newborn, with calculated carrier frequency of 1 in 25. Over 9,000 people currently have CF in the UK.
Cystic fibrosis-associated MSRA lung infections - dry powder form in a capsule-based device